Research & Development
GCI Health, HealthyWomen, and Redbook magazine are using survey insights to inform the HealthiHer movement.
Jim Boushie, director of respiratory marketing at Boehringer Ingelheim (BI) and David Laros, VP of analytics and commercial effectiveness at Aptus Health, came together to lead a joint ePharma session in March titled "Synchronized HCP and consumer campaigns: At the point of care and beyond."
Marketers discuss the biggest catalysts for use of behavioral science techniques in marketing.
As researchers and analysts, we interact with a wide array of market research pros in the health and wellness space.
Novartis Oncology taps Pfizer exec as CEO; healthcare jobs become the largest source of U.S. employment; HHS nominee wary about drug-pricing negotiations
Cancer Research UK's 'Right Now' brand campaign will return in 2018 with a new focus highlighting the impact that research has on people suffering with cancer.
Pharma R&D return on investment falls to eight-year low; FDA approves Pfizer's biosimilar to J&J's Remicade; Novartis to downsize generics business
It turns out the real goal is going after Washington's favorite whipping boy — high drug prices.
FDA approves Novo's diabetes drug; Walgreens undergoes rebranding in the wake of CVS-Aetna merger; pharma increasingly transparent about clinical trial data
Our understanding of how cancer develops and thrives has grown.
Teva reports lower-than-expected Q3 earnings; BI and Dicerna partner in NASH drug development; AstraZeneca's experimental asthma drug fails in Phase-III
Do you recall what President Trump tweeted right after Merck's Kenneth Frazier resigned from his American Manufacturing Council?
Non-profit challenges Gilead's Sovaldi patent; The Medicines Company to cut hundreds of jobs; Amgen ends R&D for experimental CETP drug
Susan G. Komen and the Breast Cancer Research Foundation are focusing on raising awareness and research money for the deadliest forms of the disease.
AI complements what we in pharma have always done best — respond to medical needs quickly and find solutions.
A New York county sues drugmakers over opioid marketing; AstraZeneca files suit against GSK exec; Thermo Fisher acquires biologics firms
Sanofi ties price increases to growth rate; Regeneron to target 7,000 docs on new eczema drug Dupixent; NIH and biotech execs meet White House officials
This is likely due, in part, to the increasingly complex nature of new specialty drugs.
The drugmaker's video asks people in New York and San Francisco about their ideas for great inventions.
These facilities may be more prone to attack because there are more people at them with access to private patient data, whether to conduct medical research or educate new healthcare professionals.
Lilly to invest $850 million in the U.S.; President Trump gives GOP leaders ultimatum on healthcare bill; Pfizer, Merck KGaA receive FDA approval for Bavencio
Biologics prompt asthma marketers to catch their collective breath as innovation has resulted in a rise of payer blockades and sky-high prices
Researchers question relationship between R&D costs and drug prices; Alexa uses WebMD to answer health questions; lawmakers push GAO to investigate orphan drugs
In our struggle with the bean counters and the stockbrokers, can't we make patient needs a priority, too?
Finally, a Congress and president who see pharma as a resource and not a villain, Flaum writes.
Pharma industry remains focused on Alzheimer's, despite setbacks; few new diabetes drugs in development; the FDA issues complete response letter to Trevena
Novo Nordisk CEO describes 'volatile' pricing environment; Lilly to cut 200 research and development jobs; pharma opts out of Super Bowl this year
Takeda to acquire Ariad for $4.6 billion, Merck pairs with Incyte for Keytruda combo drug collaboration; Sanofi announces autoimmune research deal
The merger of Quintiles and IMS Health closed in October.
The partnership allows Sermo to expand the reach of its research initiatives and Everyday Health to scale its targeted advertising on the social platform.